Aurubis AG (NDA)
XETRA Stock Exchange · Germany · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 131.50 |
|---|---|
| 52-week range | 104.80 – 225.20 |
| Return, 1 month / 3 months | −23.1% / −26.6% |
| Return, 1 year / 3 years | +25.9% / +92.0% |
| Trend | Below its 200-day average |
| RSI (14) | 21 |
| Volatility (1 year) | 40.0% |
| Worst drawdown (1 year) | -40.0% |
| Average daily value traded | 24.26M EUR |
| Dividend yield | 1.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Aurubis is a copper producer based in Germany. It operates smelters and refineries that turn copper concentrates and recycled materials into copper cathodes, wire rod and other copper products, and it also recovers precious metals and other by-products during processing. Its customers are industrial manufacturers and metal processors, and its recycling operations handle scrap and electronic materials. The company supplies copper and related metals to markets in Europe and beyond.
The shares are listed on the XETRA Stock Exchange in Germany under the code NDA, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Aurubis AG (NDA) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 131.50 on 22 October 2026.
Its price-based Market X-Ray is 42 out of 100 (a weak price profile), ranking 465 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 25.9% and over the last three months it fell 26.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 23 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -24.4% | ||
| From 52-week high | -40.0% | ||
| Momentum | 37 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -26.6% | ||
| 6-month return | -31.9% | ||
| 12-month return, skipping the last month | 63.8% | ||
| Stability (higher is calmer) | 36 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 40.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -40.0% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 24.26M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.2% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −15.7% |
|---|---|
| 1 month | −23.1% |
| 3 months | −26.6% |
| 6 months | −31.9% |
| 1 year | +25.9% |
| 3 years | +92.0% |
| 5 years | +96.9% |
Signals
| 50-day / 200-day average | 165.35 / 173.86 |
|---|---|
| Golden / death cross (60 days) | Death, 12 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.90 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 13 Feb 2026 | EUR 1.6000 |
| 4 Apr 2025 | EUR 1.5000 |
| 16 Feb 2024 | EUR 1.4000 |
| 17 Feb 2023 | EUR 1.8000 |
| 18 Feb 2022 | EUR 1.6000 |
| 22 Feb 2021 | EUR 1.1320 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.